Aclaris Therapeutics, Inc. (ACRS) Institutional Ownership

Ownership Summary

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) showed up in the 13F filings of 119 institutional investors as of December 2025.

• These investors held 70.2% of outstanding shares in December 2025, down from 70.5% in September 2025.
• Their total shares held in ACRS increased 0.18% quarter over quarter, and separately, investors owning Aclaris Therapeutics increased 22.68% from a year ago.
• Of these 119 funds, 58 grew their exposure to Aclaris Therapeutics, 40 cut back, and 21 maintained positions.
• Altogether, these fund groups held 86.11Mn shares in ACRS by December 2025, up by 152.33K shares quarter on quarter, and down 3.34Mn shares year over year.
• BML Capital Management, LLC is the top holder of Aclaris Therapeutics as of December 31, 2025, with 14.25Mn shares representing 11.62% of outstanding stock.
• The largest buyers of Aclaris Therapeutics for the quarter ending December 2025 were Deep Track Capital, LP (9.34Mn), RA CAPITAL MANAGEMENT, L.P. (6.8Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.17Mn), Frazier Life Sciences Management, L.P. (4.93Mn), BALYASNY ASSET MANAGEMENT L.P. (3.36Mn).
• The biggest sellers of Aclaris Therapeutics for the quarter ending December 2025 included Vivo Capital, LLC (2.22Mn), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (1.9Mn), D. E. Shaw & Co., Inc. (1.2Mn), ADAR1 Capital Management, LLC (1.1Mn), Goldman Sachs Group Inc (676.31K).
• According to Business Quant data, leading holders of ACRS for December 2025 are BML Capital Management, LLC (14.25Mn), Deep Track Capital, LP (9.34Mn), BlackRock, Inc. (7.41Mn), RA CAPITAL MANAGEMENT, L.P. (6.8Mn), Vivo Capital, LLC (6.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.17Mn), Frazier Life Sciences Management, L.P. (4.93Mn), Rock Springs Capital Management LP (4.47Mn), Decheng Capital LLC (4.04Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.87Mn).